Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents

Tumors Resistant to Checkpoint Inhibitors Can Become Sensitive after Treatment with Vascular Disrupting Agents

Immune therapy improves cancer outcomes, yet many patients do not respond. This pre-clinical study investigated whether vascular disrupting agents (VDAs) could convert an immune unresponsive tumor into a responder. CDF1 mice, with 200 mm<sup>3</sup> C3H mammary carcinomas in the right re...

Full description

Bibliographic Details
Main Authors:	Michael R. Horsman, Thomas R. Wittenborn, Patricia S. Nielsen, Pernille B. Elming
Format:	Article
Language:	English
Published:	MDPI AG 2020-07-01
Series:	International Journal of Molecular Sciences
Subjects:	vascular disrupting agents combretastatin OXi43503 checkpoint inhibitors anti-PD-1 anti-PD-L1
Online Access:	https://www.mdpi.com/1422-0067/21/13/4778

Similar Items

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
by: Zou W, et al.
Published: (2021-07-01)

Tumour-immune dynamics with an immune checkpoint inhibitor
by: Elpiniki Nikolopoulou, et al.
Published: (2018-06-01)

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors
by: D. I. Yudin, et al.
Published: (2020-07-01)

Exploring Markers of Exhausted CD8 T Cells to Predict Response to Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma
by: Chia-Lang Hsu, et al.
Published: (2021-05-01)

Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis
by: Robin Park, et al.
Published: (2020-03-01)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4<sup>+</sup> T Cells
by: Reem Saleh, et al.
Published: (2019-10-01)

Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
by: Jiahang Mo, et al.
Published: (2020-01-01)

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment
by: Yuxiao Song, et al.
Published: (2020-08-01)

Increased occurrence of status epilepticus in patients with brain metastases and checkpoint inhibition
by: Hans Urban, et al.
Published: (2020-01-01)

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
by: Paolo A. Ascierto, et al.
Published: (2017-08-01)

Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma
by: Bonan Zhao, et al.
Published: (2021-05-01)

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
by: Ming Yi, et al.
Published: (2019-03-01)

Checkpoint inhibitors in hematological malignancies
by: Chi Young Ok, et al.
Published: (2017-05-01)

Psoriasis Vulgaris Exacerbation during Treatment with a PD-1 Checkpoint Inhibitor: Case Report and Literature Review
by: Marlies De Bock, et al.
Published: (2018-08-01)

Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
by: Juwon Lee, et al.
Published: (2021-07-01)

Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-08-01)

Anti-PD1 checkpoint inhibitor with or without chemotherapy for patients with recurrent and metastatic nasopharyngeal carcinoma
by: Ting Jin, et al.
Published: (2021-02-01)

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable
by: Alessio Cortellini, et al.
Published: (2019-02-01)

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis
by: Chuzi S, et al.
Published: (2017-06-01)

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
by: Roman Groisberg, et al.
Published: (2017-12-01)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
by: Jacek Mackiewicz, et al.
Published: (2017-03-01)

The role of immune checkpoint inhibitors in prostate cancer
by: Gabriel Surdacki, et al.
Published: (2019-03-01)

Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update With New Evidences
by: Xinyu Yan, et al.
Published: (2018-09-01)

Opportunistic autoimmune disorders potentiated by immune-checkpoint inhibitors anti-CTLA-4 and anti-PD-1
by: Yi-Chi eKong, et al.
Published: (2014-05-01)

PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
by: D. Evrard, et al.
Published: (2020-01-01)

Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
by: Maria Georganaki, et al.
Published: (2018-12-01)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
by: Ya Xu, et al.
Published: (2020-10-01)

Immune checkpoint inhibitor-induced musculoskeletal manifestations. A multicentre prospective study
by: Dimitrios Daoussis, et al.
Published: (2020-01-01)

Progressive Sarcopenia Correlates with Poor Response and Outcome to Immune Checkpoint Inhibitor Therapy
by: Sven H. H. Loosen, et al.
Published: (2021-03-01)

Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives
by: Pasquale Persico, et al.
Published: (2021-03-01)

The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
by: Ke Ma, et al.
Published: (2018-12-01)

Retreatment with anti‐PD‐1 antibody in non‐small cell lung cancer patients previously treated with anti‐PD‐L1 antibody
by: Kohei Fujita, et al.
Published: (2020-01-01)

Mechanism and potential predictive biomarkers of immune checkpoint inhibitors in NSCLC
by: Jialin Qu, et al.
Published: (2020-07-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
by: YU Lin, et al.
Published: (2021-08-01)

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors
by: Karishma R. Rajani, et al.
Published: (2015-11-01)

Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis
by: Alberto Bongiovanni, et al.
Published: (2021-05-01)

Checkpoint Inhibition in Myeloma: Opportunities and Challenges
by: Federica Costa, et al.
Published: (2018-09-01)

Central Nervous System Demyelination Associated With Immune Checkpoint Inhibitors: Review of the Literature
by: Marcos C. B. Oliveira, et al.
Published: (2020-12-01)

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
by: Reid P. Bissonnette, et al.
Published: (2021-08-01)

Immune Checkpoint Inhibitors: Ctla-4 and Pd-1/Pd-l1 in Immunotherapy
by: Kübra KAHVECİ, et al.
Published: (2019-12-01)